All In Biotech

Drug Trial Radar · NCT02551198

Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation

Comparative Evaluation the Efficacy of 2L Polyethylene Glycol With Ascorbic Acid (PEG-Asc) and Oral Sulfate Solution (OSS) in Split Method for Bowel Preparation (The Phase III Prospective Randomized Clinical Trial)

Last checked: Nov 20, 2026Latest source record: Jan 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

184

Actual

Start

Nov 1, 2015

Primary completion

Mar 1, 2016

Study completion Sep 1, 2017

Sponsor

Lead sponsor
National Cancer Center, KoreaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Daehang Hospital
First posted
Sep 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Colonoscopy is considered by many the preferred mode of screening for colorectal cancer (CRC). The effectiveness of any CRC screening program is critically dependent on an adequate bowel preparation. For bowel preparation, effective, well-tolerated and safe methods should be applied. Recently, oral sulfate solution was adopted to Korea. Still, in Korea, there was no data of direct comparison of 2L polyethylene glycol with ascorbic acid (PEG-Asc) and oral sulfate solution (OSS) in split method for bowel preparation. Therefore, in this study, we planned the comparative evaluation the efficacy of PEG-Asc and OSS in split method for bowel preparation

Conditions

  • Healthy

Interventions

  • HAPREP®Drug

    Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc) : : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]

  • SUCLEAR®Drug

    Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adequacy of bowel preparationTime frame: on the day of colonoscopy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.